Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 6/20 | 0.48 |
| ▸ | MMP9 | P14780 | 5/20 | 0.48 |
| ▸ | MMP8 | P22894 | 5/20 | 0.48 |
| ▸ | MMP13 | P45452 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3096830 | 0.94 | MMP2 (0.49) | MMP2MMP9MMP8MMP13KDM4E | |
| SCHEMBL11948994 | 0.91 | EGFR (0.52) | MMP2MMP9MMP8MMP13KDM4E | |
| SCHEMBL11949036 | 0.90 | NR4A2 (0.47) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL3099868 | 0.89 | MMP2 (0.62) | MMP2MMP9MMP8MMP13KDM4E | |
| SCHEMBL11949028 | 0.88 | KDR (0.49) | KDM4EALDH1A1HPGD | |
| SCHEMBL3097365 | 0.85 | SMN1; SMN2 (0.46) | MMP2MMP9MMP8MMP13KDM4E | |
| SCHEMBL11949049 | 0.84 | HDAC6 (0.45) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL11949014 | 0.84 | EGFR (0.53) | MMP2MMP9MMP8MMP13KDM4E | |
| SCHEMBL3098570 | 0.84 | MMP2 (0.57) | MMP2MMP9MMP8MMP13KDM4E | |
| SCHEMBL11949031 | 0.83 | NR4A2 (0.48) | MMP2MMP9MMP8MMP13ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232410-B2 | Benzimidazoles and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232410-B2 | Benzimidazoles and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100256203-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2010-10-07 | — | — | US | disclosed |
| US-20100256203-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256203-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TBCD, TBC1D5, CFTR | MMP2 4155/4885MMP9 4514/4885MMP8 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.